Literature DB >> 1723264

Immunomodulatory activity of 9-(2-phosphonylmethoxyethyl)adenine (PMEA), a potent anti-HIV nucleotide analogue, on in vivo murine models.

V Del Gobbo1, A Foli, J Balzarini, E De Clercq, E Balestra, N Villani, S Marini, C F Perno, R Calio.   

Abstract

In order to evaluate the influence of antiviral nucleoside analogues upon the natural immune system, we investigated the immunomodulatory activity of 9-(2-phosphonylmethoxyethyl)adenine (PMEA), a nucleotide analogue with potent anti-HIV and anti-herpes activity, in a murine system. C57BL/6 mice were inoculated intraperitoneally with 10, 25 and 50 mg PMEA/kg. Mononuclear cells were isolated from their spleens, and some natural immune functions were evaluated. The results show that PMEA significantly increases the levels of natural killer (NK)-cell cytotoxicity. We also found that alpha/beta IFN production was substantially increased in PMEA-treated mice, while both IL-1 and IL-2 production was decreased. Thus, PMEA can increase some natural immunity functions, such as NK activity and IFN production. These results suggest that PMEA might be active in vivo against HIV and herpes viruses both as an immunomodulator and as an antiviral compound.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1723264     DOI: 10.1016/0166-3542(91)90059-z

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  10 in total

1.  In vitro antihepadnaviral activities of combinations of penciclovir, lamivudine, and adefovir.

Authors:  D Colledge; G Civitico; S Locarnini; T Shaw
Journal:  Antimicrob Agents Chemother       Date:  2000-03       Impact factor: 5.191

Review 2.  Adefovir dipivoxil.

Authors:  S Noble; K L Goa
Journal:  Drugs       Date:  1999-09       Impact factor: 9.546

3.  Safety of 9-(2-phosphonylmethoxyethyl)adenine (PMEA) in patients with human immunodeficiency virus infection: a pilot study.

Authors:  S Arends; E van Halteren; W Kamp; J Schokker
Journal:  Pharm World Sci       Date:  1996-01

4.  9-[2-(Phosphonomethoxy)propyl]adenine (PMPA) therapy prolongs survival of infant macaques inoculated with simian immunodeficiency virus with reduced susceptibility to PMPA.

Authors:  K K Van Rompay; J M Cherrington; M L Marthas; P D Lamy; P J Dailey; D R Canfield; R P Tarara; N Bischofberger; N C Pedersen
Journal:  Antimicrob Agents Chemother       Date:  1999-04       Impact factor: 5.191

5.  9-[2-(Phosphonomethoxy)propyl]adenine therapy of established simian immunodeficiency virus infection in infant rhesus macaques.

Authors:  K K Van Rompay; J M Cherrington; M L Marthas; C J Berardi; A S Mulato; A Spinner; R P Tarara; D R Canfield; S Telm; N Bischofberger; N C Pedersen
Journal:  Antimicrob Agents Chemother       Date:  1996-11       Impact factor: 5.191

6.  CD8+-cell-mediated suppression of virulent simian immunodeficiency virus during tenofovir treatment.

Authors:  Koen K A Van Rompay; Raman P Singh; Bapi Pahar; Donald L Sodora; Casey Wingfield; Jonathan R Lawson; Marta L Marthas; Norbert Bischofberger
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

Review 7.  Anti-AIDS drug development: challenges and strategies.

Authors:  P Mohan
Journal:  Pharm Res       Date:  1992-06       Impact factor: 4.200

8.  Inhibition of duck hepatitis B virus replication by 9-(2-phosphonylmethoxyethyl)adenine, an acyclic phosphonate nucleoside analogue.

Authors:  A J Nicoll; D L Colledge; J J Toole; P W Angus; R A Smallwood; S A Locarnini
Journal:  Antimicrob Agents Chemother       Date:  1998-12       Impact factor: 5.191

9.  (R)-9-(2-phosphonylmethoxypropyl)-2,6-diaminopurine is a potent inhibitor of feline immunodeficiency virus infection.

Authors:  T W Vahlenkamp; A De Ronde; J Balzarini; L Naesens; E De Clercq; M J van Eijk; M C Horzinek; H F Egberink
Journal:  Antimicrob Agents Chemother       Date:  1995-03       Impact factor: 5.191

Review 10.  Interferon and its inducers--a never-ending story: "old" and "new" data in a new perspective.

Authors:  Erik De Clercq
Journal:  J Infect Dis       Date:  2006-09-15       Impact factor: 5.226

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.